Advances of Drug Resistance Marker of Gemcitabine for Non-small Cell Lung Cancer

Advances of Drug Resistance Marker of Gemcitabine for Non-small Cell Lung Cancer

With the development of pharmacogenomics and pharmacogenetics, personal therapy based on genes has become one of the most effective ways to enhance chemotherapeutic effect on non-small cell lung cancer (NSCLC) patients. Much attention has been paid to validate the predictive biomarkers of chemothera...

Full description

Bibliographic Details
Main Authors: Baorui LIU, Xiaoping QIAN, Ying CHEN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2011-05-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Gemcitabine
Human equilibrative nucleoside transporter1
Ribonucleotide reductase M
Deoxicytidine kinase
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2011.05.08
Description
Summary:With the development of pharmacogenomics and pharmacogenetics, personal therapy based on genes has become one of the most effective ways to enhance chemotherapeutic effect on non-small cell lung cancer (NSCLC) patients. Much attention has been paid to validate the predictive biomarkers of chemotherapy in order to guide chemotherapy and enhance effect in general. Gemcitabine is one of the common agents treating NSCLC recently. This review is mainly about the recent reports on potential biomarkers of Gemcitabine in tailored therapy of NSCLC.
ISSN:1009-3419
1999-6187

Similar Items